Chemical and Clinical Characteristics of New Selective A2A Agonists
| Selective A2A Agonists | ||||
|---|---|---|---|---|
| Characteristics | CGS21680 (X) | MRE-0470 Binodenoson | ATL-146e (X) | CVT-3146 Regadenoson |
| Selectivity | Low | High | Very high | Moderate |
| Affinity | High | High | High | Moderate |
| Potency | Moderate | High | Very high | Moderate |
| Stable | Yes | Yes | Yes | Yes |
| Onset | 1–2 min | 1–2 min | 1–2 min | <1 min |
| Duration | >20 min | 6–12 min | 10–20 min | 3 min |
| Trials | — | 2 (phase III) | 1 in 2003 | 2 |
| FDA approved | — | To be submitted | — | YES |
Adapted with permission of (28).